Idexx Laboratories (IDXX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2005 | 09-2005 | 06-2005 | 03-2005 | 12-2004 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 67,151 | 57,768 | 52,354 | 44,579 | 47,156 |
| Marketable Securities | 65,580 | 71,688 | 78,603 | 65,622 | 90,116 |
| Receivables | 71,688 | 68,098 | 73,139 | 75,617 | 65,639 |
| Inventories | 69,369 | 80,206 | 81,765 | 78,481 | 76,424 |
| Income taxes - deferred | 13,778 | 11,869 | 11,781 | 12,473 | 13,460 |
| Other current assets | 11,679 | 10,047 | 9,689 | 9,572 | 8,797 |
| TOTAL | $299,245 | $299,676 | $307,331 | $286,344 | $301,592 |
| Non-Current Assets | |||||
| PPE Net | 65,697 | 64,936 | 63,721 | 62,744 | 62,630 |
| Investments And Advances | 0 | 2,052 | 7,583 | 12,037 | 19,687 |
| Intangibles | 118,746 | 6,062 | 27,558 | 29,718 | 124,494 |
| Other Non-Current Assets | 6,988 | 119,904 | 94,057 | 97,075 | 5,834 |
| TOTAL | $191,431 | $192,954 | $192,919 | $201,574 | $212,645 |
| Total Assets | $490,676 | $492,630 | $500,250 | $487,918 | $514,237 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 551 | N/A | N/A | N/A | N/A |
| Accounts payable and accrued liabilities | 19,842 | 18,404 | 16,193 | 12,957 | 14,723 |
| Accrued Expenses | 56,057 | 54,781 | 51,447 | 48,951 | 55,539 |
| Other current liabilities | 2,191 | N/A | N/A | N/A | 2,785 |
| TOTAL | $106,566 | $97,518 | $93,251 | $85,051 | $99,952 |
| Non-Current Liabilities | |||||
| Long Term Debt | N/A | N/A | N/A | N/A | 519 |
| Deferred Revenues | 7,965 | 8,343 | 8,434 | 8,617 | 10,153 |
| Other Non-Current Liabilities | 1,268 | 1,077 | 1,050 | 1,198 | 1,403 |
| TOTAL | $15,100 | $14,348 | $14,770 | $15,422 | $16,625 |
| Total Liabilities | $121,666 | $111,866 | $108,021 | $100,473 | $116,577 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 127,409 | 128,221 | 130,216 | 130,378 | 131,636 |
| Common Shares | 4,594 | 4,579 | 4,559 | 4,533 | 4,522 |
| Retained earnings | 396,936 | 376,909 | 356,305 | 336,372 | 318,682 |
| Other shareholders' equity | 2,086 | 4,665 | 6,540 | 10,143 | 11,639 |
| TOTAL | $369,010 | $380,764 | $392,229 | $387,445 | $397,660 |
| Total Liabilities And Equity | $490,676 | $492,630 | $500,250 | $487,918 | $514,237 |